1Raymond E,Chaney S G,Taama A,et al. Oxaliplatin:A review of preclinical and clinical studies[J].Ann Oncol,1998,9(10):1053-1071.
2Levi F,Misset J L,Brienza. Achronopharmacologic phaseⅡclinical tial with 5-fluorouracil,folinicacid,and oxaliplatin using an ambulatorymultichannel programmable pump:high antitumor effectiveness against metastasis colorectal cancer[J].Cancer,1992,69(4):893-900.
3Levi F,Perpoint B. A multicenter phaseⅡtrial of intensified chronotherapy with oxaliplatin,5-fluorouracil and folinic acid in padents with previous untreated metastatic colorectal cancer(Abstr)[J].Proc Am soc clin oncol,1997,16(5):266.
5Misset J L,Brienza S,Taamma A. Pharmacokinetics,urinary and fecal excretion of oxaliplatin in cancer patients[J].Am Ass Cancer Res Meeting abstract,1996,5(37):1252-1255.
6Grolleau F,Gamelin L,Boisdron-celle M,et al. A possible Explanation for a Neurotoxic Effect of the Anticancer agent oxaliplatin on Neuronal Volgage-Gated Sodium channels[J].The American Physiological Society,2001,85(5):2293-2297.
7Mckeage M J,Hsu T,Screnci D. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs[J].British journal of Cancer,2001,85(8):1219-1225.
8Cascinu S,Catalano V,Cordella L,et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemothera in advanced colorectal cancer:a randomized,double-blind,placebo-controlled trial[J].Clin Oncol,2002,20(16):3478-3483.
9Allain P,Heudi O,Cailleux A. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients[J]. Drug Metab Dispos,2000,28(11):1379-1384.
10Rossman T G ,Goncharova E I. Spontaneous mutagenesis in mammalian cells is caused mainly by oxidative events and can be blocked by antioxidants and metallothionein[J]. Mutat Res, 1998,402(1-2):103-110.
